Article Text

Download PDFPDF
Implications of screening for coexisting transthyretin amyloidosis and aortic stenosis
  1. Richard Cheng1,
  2. Jan Griffin2
  1. 1Division of Cardiology, University of Washington Medical Center, Seattle, Washington, USA
  2. 2Division of Cardiology, Columbia University Irving Medical Center, New York, New York, USA
  1. Correspondence to Dr Richard Cheng, Cardiology, University of Washington Medical Center, Seattle, WA 98195, USA; rkcheng{at}uw.edu

Statistics from Altmetric.com

In recent years, transthyretin cardiac amyloidosis (ATTR-CA) has transformed from a historically under-recognised disease to a crucial concern in cardiology driven by increased awareness, advent of non-invasive confirmatory algorithms using nuclear scintigraphy and development of effective pharmacological treatments. Approximately 25% of people over 85 years of age have ATTR deposition in the myocardium at autopsy, while severe aortic stenosis (AS) affects >3% of individuals over 75 years. On the background of an ageing population, with both wildtype ATTR-CA and AS highly prevalent in older adults, the coexistence of ATTR-CA with AS (AS-ATTR) is particularly pertinent to cardiologists.

Prior studies have demonstrated that 8%–16% of patients with severe AS have coexistent ATTR (AS-ATTR)1–5 (table 1). Case ascertainment for ATTR-CA in a cohort with AS can be challenging as the two disease entities share common features, including older age, increased left ventricular (LV) wall thickness, diastolic dysfunction and elevated natriuretic peptides. Conceptually, a natural assumption may be that the two pathological processes are summative, specifically that the increased afterload from AS in combination with restrictive filling from infiltration with ATTR would result in more advanced disease and worse outcomes than either entity in isolation.

View this table:
Table 1

Variables from studies comparing AS-ATTR with lone AS that significantly differed between the two disease states

In the current study, Patel and colleagues6 seek to better characterise the AS-ATTR cohort in comparison with AS alone, ATTR-CA alone, and older age controls without AS or ATTR-CA. A total of 583 patients were recruited from four prospective cohorts: (1) 81 controls from a sample of older adult patients of European origin; (2) 36 patients with AS-ATTR from two prospective observational studies in the UK and Vienna, Austria, in which patients 75 years or older with severe AS referred for a transcatheter aortic valve implantation (TAVI) underwent pre-TAVI nuclear …

View Full Text

Footnotes

  • Twitter @RichardKCheng2

  • Contributors Both authors have read and approved the manuscript. Both authors contributed significantly to the final manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Valvular heart disease
    Kush P Patel Paul Richard Scully Christian Nitsche Andreas A Kammerlander George Joy George Thornton Rebecca Hughes Suzanne Williams Therese Tillin Gabriella Captur Liza Chacko Andrew Kelion Nikant Sabharwal James D Newton Simon Kennon Mick Ozkor Michael Mullen Philip N Hawkins Julian D Gillmore Leon Menezes Francesca Pugliese Alun D Hughes Marianna Fontana Guy Lloyd Thomas A Treibel Julia Mascherbauer James C Moon